New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately t...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ACIP Expands Shingrix Recs; Updates Pneumococcal Vax Guidance ACIP Expands Shingrix Recs; Updates Pneumococcal Vax Guidance
The committee voted to recommend that immunocompromised adults aged 19+ be vaccinated against shingles, and that adults with certain risk factors or aged 65 and older receive a pneumococcal vaccine.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 22, 2021 Category: Internal Medicine Tags: Infectious Diseases News Source Type: news

What Causes Irritability?
Discussion Child abuse or non-accidental trauma is a clinical diagnosis. It is the constellation of history, physical examination, radiographic evaluation, laboratory testing and investigation that determines if child abuse has occurred. Irritability caused by fractures or other trauma can be a presenting symptom of abuse. Fractures can be a presentation but they are also common problems not associated with abuse. Femoral shaft fractures are estimated to account for only 1.6% of all fractures in children, therefore they are potentially more suspicious for child abuse. A review of femur fractures can be found here. A review...
Source: PediatricEducation.org - October 18, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

EMA Recommends VAXNEUVANCE Pneumococcal Vaccine for Approval EMA Recommends VAXNEUVANCE Pneumococcal Vaccine for Approval
The vaccine, which received FDA approval in July, protects against 15 strains of Streptococcus pneumoniae.International Approvals (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 15, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Alert Source Type: news

Fully vaccinated Florida man DIES from covid, MSN implies it's the fault of unvaccinated people
(Natural News) A North Palm Beach man is dead after contracting post-vaccination “covid pneumonia.” And the mainstream media – MSN in particular – is blaming the unvaccinated. Vincent Konidare reportedly died on Sept. 19 after testing “positive” for the Wuhan coronavirus (Covid-19) on Aug. 2. Vincent’s wife Jaime told the media that her now-deceased husband... (Source: NaturalNews.com)
Source: NaturalNews.com - October 15, 2021 Category: Consumer Health News Source Type: news

Allen West Goes on Unhinged Anti-Vaccine Tirade Amid COVID Hospitalization
The unvaccinated ex-congressman seemed to learn nothing from being sent to the emergency room with COVID-related pneumonia and low oxygen. (Source: Reuters: Health)
Source: Reuters: Health - October 10, 2021 Category: Consumer Health News Source Type: news

Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection against Lower Respiratory Infections in Older Adults
RARITAN, N.J., October 2, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV, demonstrating vaccine efficacy of 80 percent (CI, 52.2-92.9%) in adults aged 65 and older. The study results were presented as a late-breaking abstract at the virtual IDWeek 2021 conference on October 2.“The findings from our CYPRESS study are very encouraging as we seek to deliver a long-awaited preventive vaccine to stave off the...
Source: Johnson and Johnson - October 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pneumococcal vaccination reduces antibacterial failure and costs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news

Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
RARITAN, N.J., September 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the initiation of its Phase 3 EVERGREEN study. The study will evaluate the efficacy, safety and immunogenicity of Janssen’s investigational adult vaccine against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), when compared with placebo in approximately 23,000 adults aged 60 years and older throughout North America and a selection of countries across Europe, Asia and the Southern Hemisphere.The EVERGREEN study was initiated based on positive results from the Phase...
Source: Johnson and Johnson - September 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Race against the virus: the Oxford AstraZeneca COVID-19 vaccine journey
In late December 2019, a cluster of unusual pneumonia cases - now known to be the first human cases of COVID-19 - were reported in Wuhan, China. Thanks to the quick action of an Oxford scientist and her team, work on the response to the new virus began. Members of the public have the opportunity to hear the story of the Oxford AstraZeneca COVID-19 vaccine at a free online event next month. (Source: University of Bristol news)
Source: University of Bristol news - September 28, 2021 Category: Universities & Medical Training Tags: Health, Public engagement; Institutes, Institutes, Elizabeth Blackwell, Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences, Faculty of Health Sciences, Translational Healt Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mesothelioma Research, COVID Findings Featured at IASLC Conference
This study, performed during the pre-vaccine period of the pandemic, once again demonstrates the importance of vaccination against COVID-19,” said Dr. Susana Cedres, a medical oncologist with Vall d’Hebron Hospital. “Malignant pleural mesothelioma patients are particularly vulnerable to COVID-19.” Cedres said since the subsequent rollout of the COVID-19 vaccines, no positive cases have been attributed to pleural mesothelioma patients at the hospital. The average age of the seven patients was 62. All had the epithelioid histology of mesothelioma and two were receiving oncologic treatment at the...
Source: Asbestos and Mesothelioma News - September 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

The Gates Foundation ’s 2021 Report Shows That Childhood Vaccinations Dropped During the Pandemic—But There’s a Bright Side
This time last year, the Bill and Melinda Gates Foundation warned of a grim potential side effect from the COVID-19 pandemic: its disruptions to routine medical care could erase 25 years of progress on childhood vaccination, setting back global health by decades. The 2021 installment of the foundation’s annual Goalkeepers report, which details progress on 18 metrics related to global health, equity and sustainability, contains some good news and some bad news. Childhood vaccination rates have suffered during the pandemic—but only about half as much as the Gates Foundation originally predicted, signaling that ma...
Source: TIME: Health - September 14, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 embargoed study healthscienceclimate Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Africa: Messenger RNA - How It Works in Nature and in Making Vaccines
[The Conversation Africa] Vaccines have long been an integral part of public health programmes around the world, reducing the spread and severity of infectious diseases. The success of immunisation strategies to protect children from diseases like polio, hepatitis B, and measles, and adults from influenza and pneumococcal disease, can be seen globally. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 7, 2021 Category: African Health Source Type: news

Adults need to take seriously vaccines for other diseases besides covid-19 and flu
Thousands of them get sick annually from illnesses — such as pertussis, shingles, human papillomavirus and pneumonia — that could have been prevented by vaccination. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - September 6, 2021 Category: Consumer Health News Authors: Marlene Cimons Source Type: news

15-Valent Pneumococcal Vaccine Shows Promise in Infants 15-Valent Pneumococcal Vaccine Shows Promise in Infants
In a recent study, the 15-valent pneumococcal conjugate vaccine Vaxneuvance was noninferior to the currently available 13-valent pneumococcal vaccine in healthy infants.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - September 3, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Risk for Asthma at Age 4 Years Higher After Pneumonia in Infancy
Risk slightly higher after introduction of nationwide pneumococcal conjugate vaccine (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 1, 2021 Category: Respiratory Medicine Tags: Family Medicine, Infections, Pediatrics, Pulmonology, Allergy, Journal, Source Type: news

An oral history of Oxford/AstraZeneca: ‘Making a vaccine in a year is like landing a human on the moon’
It has shipped more than a billion doses, saved countless lives – and faced controversy over its safety and supply. Here, some of those who created the vaccine tell the story of their epic race against the virusIn December 2019, hospitals in Wuhan, China, reported that they were dealing with dozens of cases of pneumonia of an unknown cause. They soon identified the disease as being caused by a novelcoronavirus.Teresa Lambe,associateprofessor, Jenner Institute My brother lived in China, so whenever there was an emerging or break pathogen there, I used to follow it. I remember thinking very early on that this was proba...
Source: Guardian Unlimited Science - August 28, 2021 Category: Science Authors: Oliver Franklin-Wallis Tags: Vaccines and immunisation Coronavirus Infectious diseases Medical research Microbiology Science World news Health Society AstraZeneca University of Oxford Source Type: news

Universal Pneumococcal Vaccines May Increase Antibiotic Resistance Universal Pneumococcal Vaccines May Increase Antibiotic Resistance
Universal vaccines won't necessarily reduce antibiotic resistance in Streptococcus pneumoniae, but they may necessitate changes in vaccine policy.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - August 26, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Wisconsin lawmaker asks for prayers for colleague with COVID
The office of a Wisconsin lawmaker who has been an outspoken critic of vaccine and mask mandates has declined to update his condition, even as a fellow legislator asked for prayers, saying the state senator was hospitalized with COVID-19-induced pneumonia (Source: ABC News: Health)
Source: ABC News: Health - August 24, 2021 Category: Consumer Health News Tags: Health Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 2, 2021 Category: Drugs & Pharmacology Source Type: news

Influenza and pneumococcal vaccination in elderly cost saving in Germany
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news

Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 29, 2021 Category: Drugs & Pharmacology Source Type: news

Community-acquired bacterial meningitis
Progress has been made in the prevention and treatment of community-acquired bacterial meningitis during the past three decades but the burden of the disease remains high globally. Conjugate vaccines against the three most common causative pathogens (Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae) have reduced the incidence of disease, but with the replacement by non-vaccine pneumococcal serotypes and the emergence of bacterial strains with reduced susceptibility to antimicrobial treatment, meningitis continues to pose a major health challenge worldwide. In patients presenting with bacterial m...
Source: Current Awareness Service for Health (CASH) - July 28, 2021 Category: Consumer Health News Source Type: news

CDC: Advisory Committee on Immunization Practices (ACIP)
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is hosting a virtual meeting on September 29-30, 2021. The agenda will include discussions on cholera vaccine, hepatitis vaccines, herpes zoster vaccines, orthopoxvirus vaccine, pneumococcal vaccine, and tickborne encephalitis vaccine. Includes information on how to submit public comments or request permission to make a public comment during the meeting. Registration is not required and the meeting is open to the public, available online via a live webcast. (Source: Federal Register updates via the Rural Assistance Center)
Source: Federal Register updates via the Rural Assistance Center - July 26, 2021 Category: Rural Health Source Type: news

New Merck pneumonia vaccine OK'd in US weeks after Pfizer's
U.S. regulators have approved a new pneumonia vaccine from Merck, more than a month after OK'ing an improved version of rival Pfizer’s shot (Source: ABC News: Health)
Source: ABC News: Health - July 16, 2021 Category: Consumer Health News Tags: Health Source Type: news

FDA Approves Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults
KENILWORTH, N.J.--(BUSINESS WIRE)-- (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) (pronounced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 16, 2021 Category: Drugs & Pharmacology Source Type: news

In Texas-Mexico Border Towns, COVID-19 Has Had an Unconscionably High Death Toll
Alfredo “Freddy” Valles was an accomplished trumpeter and a beloved music teacher for nearly four decades at one of the poorest middle schools in El Paso, Texas. He was known for buying his students shoes and bow ties for their band concerts, his effortlessly positive demeanor and his suave personal style—“he looked like he stepped out of a different era, the 1950s,” says his niece, Ruby Montana. While Valles was singular in life, his death at age 60 in February 2021 was part of a devastating statistic: He was one of thousands of deaths in Texas border counties—where coronavirus mortalit...
Source: TIME: Health - June 22, 2021 Category: Consumer Health News Authors: René Kladzyk, Phil Galewitz and Elizabeth Lucas | El Paso Matters and KHN Tags: Uncategorized COVID-19 Source Type: news

Twenty-Year Impact of Pneumococcal Conjugate Vaccines Twenty-Year Impact of Pneumococcal Conjugate Vaccines
A new report highlights the 20-year effect of pneumococcal conjugate vaccines in preventing pneumococcal disease in children.Emerging Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2021 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 16, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves 20-Valent Pneumococcal Vaccine (Prevnar) FDA Approves 20-Valent Pneumococcal Vaccine (Prevnar)
The vaccine is capable of protecting against 20 serotypes involved in most cases of invasive pneumonia and pneumococcal disease in the US. This may be a significant advance in reducing pneumonia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2021 Category: Consumer Health News Tags: Infectious Diseases News Alert Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for Adults Ages 18 Years or Older
First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia,1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 8, 2021 Category: Drugs & Pharmacology Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Memorial Sloan Kettering Opening New Mesothelioma Clinical Trial
Memorial Sloan Kettering Cancer Center in New York City will begin recruiting soon for its latest clinical trial involving patients with malignant pleural mesothelioma and the expanded use of immunotherapy. The single-center, phase I study will explore the effectiveness of pembrolizumab in combination with intensity-modulated pleural radiation therapy, known as IMPRINT, in treating unresectable disease. Pembrolizumab, also known by the brand name Keytruda, was approved by the U.S. Food and Drug Administration in 2020 for treatment of a small subset of mesothelioma patients. As a well-known immunotherapy drug, pemb...
Source: Asbestos and Mesothelioma News - May 26, 2021 Category: Environmental Health Authors: Matt Bardsley Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pfizer begins testing COVID-19 booster shot with pneumococcal vaccine
The pharmaceutical company Pfizer is studying a third dose of the vaccine and a pneumococcal vaccine candidate. (Source: Reuters: Health)
Source: Reuters: Health - May 25, 2021 Category: Consumer Health News Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How a False Sense of Security, and a Little Secret Tea, Broke Down Taiwan ’s COVID-19 Defenses
All it took to break down the world’s most vaunted COVID-19 defense was a little secret tea. After almost 18 months of nearly unblemished success keeping the coronavirus pandemic at bay—including the world’s longest streak of case-free days—Taiwan is now in the grip of its first major COVID-19 surge. Total cases, which had been below 1,300 through the entire pandemic, have surged to more than 3,100 in the span of a week. Many offices have sent workers home, the streets of the capital Taipei have cleared out and the government has begun scrambling to secure vaccines to improve one of the worst inocul...
Source: TIME: Health - May 21, 2021 Category: Consumer Health News Authors: Michael Zennie and Gladys Tsai / Taipei Tags: Uncategorized COVID-19 feature overnight Taiwan Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Anthony Fauci, 100 Days Into the Biden Administration, Is Finally Getting to Do His Job
When Dr. Anthony Fauci arrived at 1600 Pennsylvania Ave. for his first White House press briefing under the new Biden Administration, he could see things would be different. It was the day after the Inauguration, and President Joe Biden was eager to get the country’s COVID-19 response back on track. Five minutes before he addressed the public, Fauci spoke with the new President. “He said, ‘I want you to just go and tell the science, explain to people that if we make mistakes, we’re going to fix the mistakes and we’re not going to dwell on the mistakes. Let science be communicated to the public...
Source: TIME: Health - May 18, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Pneumococcal Vaccines Safe for Pregnant Women With HIV Pneumococcal Vaccines Safe for Pregnant Women With HIV
Pneumococcal vaccines PCV-10 and PPV-23 are equally safe and immunogenic in pregnant women with HIV, although PPV-23 administration might be more beneficial because it includes a wider range of serotypes, researchers say.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 12, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

How Long Does the Pneumonia Vaccine Last
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 27, 2021 Category: General Medicine Source Type: news

World Immunization Week 2021
Vaccines bring us closer to a healthier world 22 April 2021 – The last week of April each year we celebrate the World Immunization Week. This year, the celebration amid the COVID-19 pandemic reminds us that vaccines can bring us closer to a healthier, more prosperous world, where no one suffers or dies from a vaccine-preventable disease. "Vaccines are one of the most effective public health interventions that have saved millions of lives over the years.This year, the importance of vaccination is clearer than ever. Safe and effective vaccines can be a game changer in the global response to the COVID-19 pandem...
Source: WHO EMRO News - April 22, 2021 Category: Middle East Health Source Type: news

What Are Toxin-Mediated Diseases?
Discussion A poison is a generic term for “a substance with an inherent property that tends to destroy life or impair health.” A toxin is more specific and is “any poison produced by an organism, characterized by antigenicity in certain animals and high molecular weight, and including the bacterial toxins that are the causative agents of tetanus, diphtheria, etc., and such plant and animal toxins as ricin and snake venom.” A toxin does not include those substances that are made synthetically produced. Venom is also a toxin that is used by animals and insects for predation or defense which can cause ...
Source: PediatricEducation.org - April 12, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

SII to start supplying 1st made-in-India pneumococcal conjugate vaccine to Centre from Wednesday
The SII has to supply 2.4 crore doses of the vaccine to the Health Ministry by December 2021. It will be sent to 37 consignees all over India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 6, 2021 Category: Pharmaceuticals Source Type: news